Skip to main content
Clinical Trials/NCT04013997
NCT04013997
Completed
N/A

Safety of Exoskeleton-assisted Walking in SCI Inpatient Rehabilitation

Icahn School of Medicine at Mount Sinai1 site in 1 country10 target enrollmentAugust 11, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Spinal Cord Injuries
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
10
Locations
1
Primary Endpoint
Number of fall
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

To assess how safe the exoskeleton, EksoGT, is to use for acute inpatient rehabilitation, if it helps people to walk better than with traditional walking training methods, or if they have any other effects (better or worse) on recovery.

Detailed Description

Wearable robots that assist with walking over ground are now available in rehabilitation centers. However, the study team did not know how soon it is safe to start using these devices for rehabilitation, if they helped people to walk better than with traditional locomotor training methods, or if they had any other effects (better or worse) on recovery. The study team's objectives of this study were to explore the safety, feasibility, and efficacy of using the powered exoskeleton, EksoGT, to provide a locomotor training intervention in acute inpatient rehabilitation for persons with spinal cord injury (SCI) who were eligible for locomotor training. Aim 1 examined the safety of exoskeleton use for persons with SCI during inpatient rehabilitation. Measures for this aim analyzed the amount of falls as well as types and counts of other adverse events (AE) for both serious and non-serious events as outlined by the FDA. Aim 2 helped determine the feasibility of exoskeleton use during inpatient rehabilitation for SCI by monitoring the time from admission to first stand in the device, accumulated step count/time in the device, and progression of locomotor training frequency, duration, and intensity. Aim 3 explored the potential for associations between exoskeleton use in inpatient rehabilitation and body functions and activities associated with walking. Measures for this aim included: American Spinal Injury Association (ASIA) Impairment Scale (AIS), Neurological Level of Injury (NLI), Upper and Lower Extremity Motor Scores, and Functional Index Measure (FIM). Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians would identify patients admitted to the unit who may be eligible for the study. Consent forms were given to prospected participants. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determines it is safe for participants to begin standing, and continued until the participant is discharged from inpatient rehabilitation. The study team monitored participants for adverse events (safety), tracked the amount of walking provided during the inpatient stay (feasibility), and explored the improvement of activities of daily living (functioning) compared to the matched control group who didn't have Ekso training and were chosen by a retrospective chart review.

Registry
clinicaltrials.gov
Start Date
August 11, 2017
End Date
June 12, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Miguel Escalon

Assistant Professor

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or greater
  • Height between 5'2" and 6'2" (1.6 meters to 1.9 meters)
  • Weight less than 220 pounds (100 kilograms)
  • Near Normal range of motion (ROM), as follows:
  • Hip: 5 degrees of extension; 110 of flexion
  • Knee: Full extension to 110 of flexion
  • Ankle: at least 0 of dorsiflexion to 25 of plantarflexion
  • Are eligible for locomotor training as part of inpatient rehabilitation
  • Independent with static sitting balance
  • Sufficient function upper extremity strength to manage walking aid (front-wheeled walker, platform walker, or crutches)

Exclusion Criteria

  • Uncontrolled cardiovascular conditions (i.e. heart failure, angina, hypertension)
  • Inability to stand upright due to orthostatic hypotension
  • Body characteristics that do not fit within exoskeleton limits
  • Upper leg length discrepancy \> 0.5" or lower leg discrepancy \>0.75"
  • Skin integrity issues in areas that would contact the device or that would likely be made worse by device use
  • Pregnancy
  • Colostomy
  • Non-English Speaking
  • The participant is able to walk better with exoskeleton assistance at baseline
  • Any other issue that might prevent safe standing or walking

Outcomes

Primary Outcomes

Number of fall

Time Frame: 2 years

Number of falls to assess safety

Number of adverse events

Time Frame: 2 years

types and counts of the adverse events for both serious and non-serious events as outlined by the FDA to assess safety

Secondary Outcomes

  • Lower Extremity Motor Scores (LEMS)(2 years)
  • The time from admission to first stand in the device(2 years)
  • Proportion of walking time(2 years)
  • Neurological Level of Injury (NLI)(2 years)
  • Functional Independence Measure (FIM)(2 years)
  • Accumulated step count in the device(2 years)
  • Accumulated step time in the device(2 years)
  • American Spinal Injury Association (ASIA) Impairment Scale (AIS)(2 years)
  • Upper Extremity Motor Scores (UEMS)(2 years)

Study Sites (1)

Loading locations...

Similar Trials